greeksoup/ stock research
Stock research / United States / Funds / Frazier Life Sciences Management, L.P.

Frazier Life Sciences Management, L.P.

CIK 1892134 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Frazier Life Sciences Management, L.P. reported 41 US-listed holdings worth $4.59 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Mirum Pharmaceuticals Inc. (19.6%), Newamsterdam Pharma Company (13.3%) and Erasca Inc. (10.0%). Against the quarter before, it opened 6 positions, added to 8, trimmed 1 and sold out of 3.

Reported holdings$4.59B+18.2% on Q1 2026
Positions41+3 on Q1 2026
The largest ten73.6%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
Added toHeldTrimmed
MIRM19.6%NAMS13.3%ERAS10.0%MBX8.0%ARQT5.6%TRVI4.0%KRYS3.9%MAZE3.3%PHAT2.9%PVLA2.9%BBIO2.5%IRON2.2%CYTK2.2%DYN1.5%27 more18.0%

The 14 largest of its 41 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $2.50 billion in 53 positions$2.50BQ3 24Q4 2024: $2.41 billion in 50 positions$2.41BQ4 24Q1 2025: $2.19 billion in 47 positions$2.19BQ1 25Q2 2025: $2.50 billion in 49 positions$2.50BQ2 25Q3 2025: $3.34 billion in 47 positions$3.34BQ3 25Q4 2025: $3.72 billion in 40 positions$3.72BQ4 25Q1 2026: $3.89 billion in 38 positions$3.89BQ1 26Q2 2026: $4.59 billion in 41 positions$4.59BQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What it did on the quarter

Opened 6Added 8Held 26Trimmed 1Sold out 3
Opened: 6Added: 8Held: 26Trimmed: 1Sold out: 3

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 6

  1. Parabilis Medicines Inc. Com PBLS$52.6 million
  2. Achieve Life Sciences Inc. ACHV$49.7 million
  3. Design Therapeutics Inc. DSGN$26.2 million
  4. Shattuck Labs Inc. STTK$26.0 million
  5. Kailera Therapeutics Inc. KLRA$24.2 million
  6. Relay Therapeutics Inc. RLAY$19.0 million

Added to 8

  1. Newamsterdam Pharma Company NAMS+1.1 million shares · +7%
  2. Allogene Therapeutics Inc. ALLO+18.6 million shares · +491%
  3. Ascendis Pharma A/s ASND+91,822 shares · +69%
  4. Aura Biosciences Inc. AURA+2.0 million shares · +39%
  5. Maze Therapeatics MAZE+465,641 shares · +10%
  6. Erasca Inc. ERAS+300,000 shares · +1%
  7. Mannkind Corp. MNKD+700,000 shares · +12%
  8. Lexeo Therapeutics Inc. LXEO+400,000 shares · +9%

Trimmed 1

  1. Bridgebio Pharma Inc. BBIO-1.9 million shares · -55%

Sold out of 3

  1. Kalvista Pharmaceuticals Inc. KALV$99.9 million last quarter
  2. Revolution Medicines, Inc. RVMD$65.7 million last quarter
  3. Agios Pharmaceuticals Inc. AGIO$42.5 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Mirum Pharmaceuticals Inc. MIRM7,679,684$899.1 million19.58%no change
Newamsterdam Pharma Company NAMS18,088,902$613.0 million13.35%+1,145,128
Erasca Inc. ERAS24,975,188$457.5 million9.96%+300,000
MBX Biosciences Inc. MBX6,652,013$367.2 million8.00%no change
Arcutis Biotherapeutics Inc. ARQT9,874,511$258.9 million5.64%no change
Trevi Therapeutics Inc. TRVI9,939,447$185.4 million4.04%-100
Krystal Biotech, Inc. KRYS481,307$178.9 million3.90%no change
Maze Therapeatics MAZE5,032,915$150.2 million3.27%+465,641
Phathom Pharmaceuticals Inc. PHAT12,466,489$135.3 million2.95%no change
Palvella Therapeutics Inc. Ne PVLA882,400$134.8 million2.94%no change
Bridgebio Pharma Inc. BBIO1,548,139$115.3 million2.51%-1,900,000
Disc Medicine Inc. IRON1,354,852$99.1 million2.16%no change
Cytokinetics Inc. CYTK1,159,879$98.8 million2.15%no change
Dyne Therapeutics Inc. DYN3,153,082$70.0 million1.53%no change
Ascendis Pharma A/s ASND225,155$60.1 million1.31%+91,822
Savara Inc. SVRA9,720,852$59.9 million1.30%no change
Parabilis Medicines Inc. Com PBLS1,920,805$52.6 million1.14%new
Aura Biosciences Inc. AURA7,100,000$50.4 million1.10%+2,000,000
Achieve Life Sciences Inc. ACHV7,614,836$49.7 million1.08%new
Vor Biopharma Inc. VOR2,543,939$46.8 million1.02%no change
Allogene Therapeutics Inc. ALLO22,446,668$46.7 million1.02%+18,650,000
Tarsus Pharmaceuticals Inc. TARS728,644$45.9 million1.00%no change
Biocryst Pharmaceuticals Inc. BCRX4,009,240$40.1 million0.87%no change
Alkermes plc. ALKS700,647$36.7 million0.80%no change
Acadia Pharmaceuticals Inc. ACAD1,438,198$36.4 million0.79%no change
Zai Lab Limited ZLAB1,902,320$36.1 million0.79%no change
Mannkind Corp. MNKD6,600,000$28.1 million0.61%+700,000
Design Therapeutics Inc. DSGN1,809,854$26.2 million0.57%new
Aclaris Therapeutics Inc. ACRS4,925,374$26.1 million0.57%no change
Shattuck Labs Inc. STTK3,750,000$26.0 million0.57%new
Kailera Therapeutics Inc. KLRA1,100,000$24.2 million0.53%new
Monte Rosa Therapeutics Inc. GLUE1,000,000$24.2 million0.53%no change
Lexeo Therapeutics Inc. LXEO4,824,725$22.5 million0.49%+400,000
Relay Therapeutics Inc. RLAY1,015,693$19.0 million0.41%new
Evolus Inc. EOLS2,630,665$18.3 million0.40%no change
Immunocore Hldgs PLC IMCR484,782$15.4 million0.34%no change
Valneva SE VALN2,291,666$12.0 million0.26%no change
Newamsterdam Pharma Company500,333$10.7 million0.23%no change
Autolus Therapeutics PLC AUTL4,447,910$7.1 million0.15%no change
Xilio Therapeutics Inc. XLO422,505$4.0 million0.09%no change
Ibio Inc. Com IBIO1,953,467$3.4 million0.07%no change
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 3 it sold out of are in the box above.